Bayer’s Phase III OCEANIC-STROKE trial shows asundexian cuts recurrent ischemic stroke risk by 26% without increasing major bleeding, supporting FXIa inhibition in secondary prevention.
Written By: Karthik Teja Macharla, PharmD
Reviewed By: Pharmacally Editorial Team
Bayer reports Phase III evidence that asundexian reduces recurrent ischemic stroke risk by 26% without increasing major bleeding, according to findings published in The New England Journal of Medicine.
The global OCEANIC-STROKE trial (NCT05686070), a multicenter, randomized, double-blind study, evaluated once-daily oral asundexian (50 mg) versus placebo, both on top of standard antiplatelet therapy. The trial enrolled 12,327 patients with recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA).
Efficacy: Consistent Stroke Risk Reduction
Asundexian reduced the risk of ischemic stroke by 26% compared with placebo (cause-specific hazard ratio [csHR] 0.74; 95% CI 0.65–0.84; p<0.001). Rates of International Society on Thrombosis and Hemostasis (ISTH) major bleeding were unchanged.
The treatment effect remained consistent across key subgroups, including age, sex, stroke subtype, and background antiplatelet regimens, whether single or dual therapy, supporting broad clinical applicability.
Balanced Efficacy and Safety Profile
In addition to the primary endpoint, asundexian demonstrated favorable outcomes across multiple composite measures:
- Ischemic stroke or ISTH major bleeding
- Cardiovascular death, stroke, myocardial infarction, or major bleeding
- All-cause mortality, disabling stroke, fatal bleeding, or symptomatic intracranial hemorrhage
These results indicate a balanced efficacy and safety profile, addressing a central challenge in antithrombotic therapy.
Expert and Company Insights
Mike Sharma, principal investigator of the study, said the findings provide clearer insight into the favorable net clinical benefit of asundexian across a broad stroke population and are likely to inform future secondary prevention strategies.
Christian Rommel, Global Head of Research and Development at Bayer, described the results as a “foundational body of evidence” supporting progress in cardiovascular therapeutics.
Mechanism and Clinical Rationale
By targeting Factor XIa in the coagulation cascade, asundexian limits pathological thrombus formation while largely preserving normal hemostasis. This selective mechanism may explain the observed reduction in thrombotic events without increased bleeding risk.
The investigational therapy has received Fast Track designation from the U.S. Food and Drug Administration but is not yet approved for clinical use.
Addressing a Persistent Global Burden
Stroke affects approximately 12 million people globally each year, with 20–30% experiencing recurrent events despite available therapies. Recurrent strokes are often more disabling and carry higher mortality, underscoring the need for improved preventive strategies.
Data from OCEANIC-STROKE, first presented at the American Heart Association International Stroke Conference 2026, strengthen the case for Factor XIa inhibition as a novel therapeutic approach.
The consistency of efficacy and safety outcomes positions FXIa inhibition as a potential shift in secondary stroke prevention, pending regulatory review and further clinical integration.
Reference
Asundexian for Secondary Stroke Prevention | New England Journal of Medicine
About the Writer
Karthik Teja Macharla, PharmD is a Pharm.D. graduate with a strong interest in clinical research, pharmacovigilance, and medical writing. In his words, he is passionate about converting complex medical information into clear, evidence-based scientific communication, committed to contributing to patient safety and advancing healthcare through accurate and impactful medical content.